WO1989003672A1 - Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying - Google Patents
Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying Download PDFInfo
- Publication number
- WO1989003672A1 WO1989003672A1 PCT/FR1988/000512 FR8800512W WO8903672A1 WO 1989003672 A1 WO1989003672 A1 WO 1989003672A1 FR 8800512 W FR8800512 W FR 8800512W WO 8903672 A1 WO8903672 A1 WO 8903672A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- spraying
- administered
- nasal
- precise
- amphotericin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
Definitions
- the present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
- Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase health expenditure by increasing the length of hospital stay.
- the present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and oropharyngeal cavities.
- the three antibiotics associated in the preparation are polymyxin B, netilmicin and amphotericin B.
- the preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum spreading on the mucous membranes nasal and oropharyngeal.
- the preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump.
- Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and the vaporization of the nasal passages, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity .
- valves or pumps will be very precise. They are of course a function of the concentration of antibiotics within the preparation.
- the frequency of applications also depends on the concentration of these products.
- valve or pump must be adapted to deliver 0.5 ml each time it is pressed.
- 400 mg of polymyxin B, 360 mg of netilmicin and 2000 mg of amphotericin B are administered daily.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Abstract
The invention concerns a drug for preventing gram-negative bacillary infections and mycoses in patients at risk, comprising the association of three antibiotics: polymyxin B, netilmycin and amphotericin B, administered by precise spraying in the nasal and oropharyngeal cavities either in the form of a pressurized aerosol dispensed by a continuous or dosing valve or in the form of a nasal spray dispensed by a precise pump. Two pushers are provided with each bottle: one having a long thin cannula for introduction into the nostrils and spraying of the nasal fossae, the other having a cannula permetting generous spraying of the oropharyngeal cavity. The drug has a wide range of indications in all patients at risk of contracting a gram-negative bacillary infection or a mycosis.
Description
Médicament comprenant l'association de polymyxine B, de nétilmicine et d'amphotéricine B administré par vaporisation. Medicine comprising the combination of polymyxin B, netilmicin and amphotericin B administered by vaporization.
La présente invention concerne un médicament pour vaporisation destiné à prévenir les risques d'infection chez les malades à risques en décontami- nant les cavités nasales et oropharyngées.The present invention relates to a spray medication intended to prevent the risks of infection in patients at risk by decontaminating the nasal and oropharyngeal cavities.
Les infections à bacilles gram négatif et les mycoses sont fréquentes chez les malades à risques. Elles entraînent une morbidité importante, elles sont une des causes principales du décès de ces patients, elles aug¬ mentent les dépenses de santé en augmentant les durées d'hospitalisation. La présente invention permet de remédier à cet inconvénient. Elle com¬ porte l'association de trois antibiotiques administrée par vaporisation dans les cavités nasales et oropharyngées. Les trois antibiotiques asso¬ ciés dans la préparation sont la polymyxine B, la nétilmicine et l'ampho- téricine B. La préparation doit adhérer aux muqueuses nasales et buccales, relarguer lentement les antibiotiques et avoir une tension superficielle permettant un étalement maximal sur le muqueuses nasales et oropharyngées. La préparation est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise. Deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines et la vaporisation des fos¬ ses nasales,l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée.Gram-negative bacillus infections and yeast infections are common in at-risk patients. They cause significant morbidity, they are one of the main causes of the death of these patients, they increase health expenditure by increasing the length of hospital stay. The present invention overcomes this drawback. It includes the combination of three antibiotics administered by spraying into the nasal and oropharyngeal cavities. The three antibiotics associated in the preparation are polymyxin B, netilmicin and amphotericin B. The preparation must adhere to the nasal and oral mucous membranes, slowly release the antibiotics and have a surface tension allowing maximum spreading on the mucous membranes nasal and oropharyngeal. The preparation is administered by precise spraying either in the form of a pressurized aerosol dispensed by a continuous or metering valve or in the form of a nebulization dispensed by a precise pump. Two pushers are supplied with each bottle: one with a long and fine cannula allowing the introduction through the nostrils and the vaporization of the nasal passages, the other with a cannula allowing a broad vaporization of the oropharyngeal cavity .
Les doses distribuées par les valves ou les pompes seront très précises. Elles sont bien entendu fonction de la concentration des antibiotiques au sein de la préparation.The doses distributed by the valves or pumps will be very precise. They are of course a function of the concentration of antibiotics within the preparation.
La fréquence des applications dépend également de la concentration de ces produits.The frequency of applications also depends on the concentration of these products.
Aucun de ces antibiotiques n'étant absorbé par voie nasale, oropharyn- gée ou digestive, les posologies et donc les concentrations peuvent varier dans une très large part.None of these antibiotics being absorbed by the nasal, oropharyngeal or digestive route, the dosages and therefore the concentrations can vary to a very large extent.
Les caractéristiques et avantages de l'invention ressortent de la des¬ cription qui va suivre à titre d'exemple : pour 30 ml de préparation on associe : - sulfate de polymyxine B : 500 mgThe characteristics and advantages of the invention appear from the description which will follow by way of example: for 30 ml of preparation, the following are combined: - polymyxin sulfate B: 500 mg
FEUILLE DE REMPLACEMENT
- sulfate de nétilmicine 450 mgREPLACEMENT SHEET - netilmicin sulfate 450 mg
- amphotéricine B 2500 mg- amphotericin B 2500 mg
- alcool à 90° 1 ml- 90 ° alcohol 1 ml
- saccharinate de sodium 100 mg- sodium saccharinate 100 mg
- essence de menthe 0,02 ml- mint essence 0.02 ml
- glycérine quantité suffisante pour- glycerin sufficient amount to
30 ml La valve ou la pompe doit être adaptée pour délivrer 0,5 ml à chaque pression. On recommande 6 pressions dans la cavités oropharyngée, 3 pres- sions dans chaque narine à chaque administration et une fréquence de qua¬ tre administrations par jour. Dans cet exemple, on administre 400 mg de polymyxine B, 360 mg de nétilmicine et 2000 mg d'amphotéricine B par jour.30 ml The valve or pump must be adapted to deliver 0.5 ml each time it is pressed. We recommend 6 pressures in the oropharyngeal cavity, 3 pressures in each nostril at each administration and a frequency of four administrations per day. In this example, 400 mg of polymyxin B, 360 mg of netilmicin and 2000 mg of amphotericin B are administered daily.
Il est recommandé d'associer la vaporisation nasale et oropharyngée à une décontamination sélective du tube digestif par administration orale ou par sonde gastrique avec ces mêmes antibiotiques.It is recommended to combine nasal and oropharyngeal spraying with selective decontamination of the digestive tract by oral administration or by gastric tube with these same antibiotics.
Les indications de ce médicament sont très larges : il doit être emplo¬ yé chaque fois qu'un risque d'infection à gram négatif ou de mycose est présent : en réanimation, en hématologie, en chirurgie, en anesthesiologie, en cancérologie, etc..
The indications for this drug are very broad: it should be used whenever a risk of gram negative infection or mycosis is present: in intensive care, hematology, surgery, anesthesiology, oncology, etc. .
Claims
REVENDICATIONS
1) Médicament destiné à prévenir les risques d'infections à bacilles gram négatif caractérisé en ce qu'il comporte l'association de trois anti- giotiques : polymyxine B, nétilmicine. et amphotéricine B administrée par vaporisation dans les cavités nasales et oropharyngées.1) Medication intended to prevent the risks of infections with gram-negative bacilli, characterized in that it comprises the combination of three antibiotics: polymyxin B, netilmicin. and amphotericin B administered by spraying into the nasal and oropharyngeal cavities.
2) Médicament selon la revendication 1 caractérisé en ce que la prépa¬ ration est administrée par vaporisation précise soit sous forme d'aérosol pressurisé distribué par une valve continue ou doseuse soit sous forme de nébulisation distribuée par une pompe précise.2) Medicament according to claim 1 characterized in that the prepa¬ ration is administered by precise spraying either in the form of pressurized aerosol dispensed by a continuous valve or metering or in the form of nebulization dispensed by a precise pump.
3) Médicament selon la revendication 1 ou la revendication 2 caractéri¬ sé en ce que les doses distribuées par les valves ou les pompes sont très précises.3) Medicament according to claim 1 or claim 2 caractéri¬ se in that the doses dispensed by the valves or pumps are very precise.
4) Médicament selon l'une quelconque des revendications précédentes caractérisé en ce que deux poussoirs sont fournis avec chaque flacon : l'un disposant d'une canule longue et fine permettant l'introduction par les narines, l'autre d'une canule permettant une vaporisation large de la cavité oropharyngée.
4) Medicament according to any one of the preceding claims, characterized in that two pushers are supplied with each bottle: one having a long and fine cannula allowing the introduction through the nostrils, the other of a cannula allowing wide vaporization of the oropharyngeal cavity.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR87/14346 | 1987-10-19 | ||
FR8714346A FR2621818B1 (en) | 1987-10-19 | 1987-10-19 | MEDICINE COMPRISING THE COMBINATION OF POLYMIXIN B, NETILMICIN AND AMPHOTERICIN B BY VAPORIZATION |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989003672A1 true WO1989003672A1 (en) | 1989-05-05 |
Family
ID=9355911
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/FR1988/000512 WO1989003672A1 (en) | 1987-10-19 | 1988-10-19 | Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2624888A (en) |
FR (1) | FR2621818B1 (en) |
WO (1) | WO1989003672A1 (en) |
Cited By (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014849A1 (en) * | 1994-11-11 | 1996-05-23 | HAIDER, Angelika | Use of aminoglycosides to diagnose blood-air barrier disorders |
RU2605263C1 (en) * | 2015-11-05 | 2016-12-20 | государственное автономное научное учреждение "Институт стратегических исследований Республики Башкортостан" | Ointment with netilmicin and propolis extract for integrated treating inflammatory periodontal diseases |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL121455C (en) * | 1900-01-01 | |||
GB1018125A (en) * | 1962-11-29 | 1966-01-26 | Merck & Co Inc | Chemical products |
AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
-
1987
- 1987-10-19 FR FR8714346A patent/FR2621818B1/en not_active Expired - Lifetime
-
1988
- 1988-10-19 AU AU26248/88A patent/AU2624888A/en not_active Abandoned
- 1988-10-19 WO PCT/FR1988/000512 patent/WO1989003672A1/en unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL121455C (en) * | 1900-01-01 | |||
GB1018125A (en) * | 1962-11-29 | 1966-01-26 | Merck & Co Inc | Chemical products |
AU539563B2 (en) * | 1981-01-21 | 1984-10-04 | Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara | Primycin, doxycyline and sisomicin composition |
Non-Patent Citations (1)
Title |
---|
The Merck Index, 10ième édition, 1983, Merck & Co. (Rahway, N.J. US), voir nos. 611, 6322, 7445 * |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996014849A1 (en) * | 1994-11-11 | 1996-05-23 | HAIDER, Angelika | Use of aminoglycosides to diagnose blood-air barrier disorders |
US10124129B2 (en) | 2008-01-02 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Dispensing device, storage device and method for dispensing a formulation |
US10011906B2 (en) | 2009-03-31 | 2018-07-03 | Beohringer Ingelheim International Gmbh | Method for coating a surface of a component |
US9682202B2 (en) | 2009-05-18 | 2017-06-20 | Boehringer Ingelheim International Gmbh | Adapter, inhalation device, and atomizer |
US10124125B2 (en) | 2009-11-25 | 2018-11-13 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9724482B2 (en) | 2009-11-25 | 2017-08-08 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10016568B2 (en) | 2009-11-25 | 2018-07-10 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9943654B2 (en) | 2010-06-24 | 2018-04-17 | Boehringer Ingelheim International Gmbh | Nebulizer |
US9757750B2 (en) | 2011-04-01 | 2017-09-12 | Boehringer Ingelheim International Gmbh | Medicinal device with container |
US9827384B2 (en) | 2011-05-23 | 2017-11-28 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10220163B2 (en) | 2012-04-13 | 2019-03-05 | Boehringer Ingelheim International Gmbh | Nebuliser with coding means |
US9545487B2 (en) | 2012-04-13 | 2017-01-17 | Boehringer Ingelheim International Gmbh | Dispenser with encoding means |
US9744313B2 (en) | 2013-08-09 | 2017-08-29 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10004857B2 (en) | 2013-08-09 | 2018-06-26 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10894134B2 (en) | 2013-08-09 | 2021-01-19 | Boehringer Ingelheim International Gmbh | Nebulizer |
US11642476B2 (en) | 2013-08-09 | 2023-05-09 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10716905B2 (en) | 2014-02-23 | 2020-07-21 | Boehringer Lngelheim International Gmbh | Container, nebulizer and use |
US10099022B2 (en) | 2014-05-07 | 2018-10-16 | Boehringer Ingelheim International Gmbh | Nebulizer |
US10195374B2 (en) | 2014-05-07 | 2019-02-05 | Boehringer Ingelheim International Gmbh | Container, nebulizer and use |
US10722666B2 (en) | 2014-05-07 | 2020-07-28 | Boehringer Ingelheim International Gmbh | Nebulizer with axially movable and lockable container and indicator |
RU2605263C1 (en) * | 2015-11-05 | 2016-12-20 | государственное автономное научное учреждение "Институт стратегических исследований Республики Башкортостан" | Ointment with netilmicin and propolis extract for integrated treating inflammatory periodontal diseases |
Also Published As
Publication number | Publication date |
---|---|
AU2624888A (en) | 1989-05-23 |
FR2621818B1 (en) | 1990-12-14 |
FR2621818A1 (en) | 1989-04-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO1989003672A1 (en) | Drug comprising the association of polymyxin b, netilmycin and amphotericin b, administered by spraying | |
WO1989003673A1 (en) | Drug comprising the association of polymyxin b, tobramycin and amphotericin b administered by spraying | |
EP0390832A1 (en) | Medicinal preparation comprising the association of colistin, tobramycin and amphotericin b administered by atomization | |
ES2330415T3 (en) | SYSTEM FOR OSMOTIC SUPPLY OF PHARMACEUTICAL ACTIVE AGENTS. | |
WO2005046640A3 (en) | Multi-site drug delivery platform | |
CA2039456A1 (en) | Osmotic dosage system for liquid drug delivery | |
PT984762E (en) | DEBIT CONTROLLER CONFIGURATIONS FOR AN ACTIVE AGENT ADMINISTRATION DEVICE | |
ATE261301T1 (en) | MEDICINAL PREPARATIONS CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUGS | |
DK0998916T3 (en) | Medicines for administration to the mucosa | |
ES2104522T3 (en) | NEW MEDICINAL ADMINISTRATION SYSTEM. | |
MX170801B (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OF SEXUALLY COMMUNICABLE DISEASES | |
WO2004039351A3 (en) | Pharmaceutical compositions suitable for the treatment of ophthalmic diseases | |
US4876283A (en) | Antisnoring agent | |
WO2002007810A3 (en) | Catheter for target specific drug delivery | |
WO2005035027A3 (en) | Implantable perfusion device | |
CA2433833A1 (en) | Use of flumazenil in developing a drug for the treatment of alcohol dependence | |
CA1223210A (en) | Antisnoring agent | |
KR970032872A (en) | Drugs for the treatment of skin damage containing acetylsalicylic acid | |
FR2624017A1 (en) | Medicament comprising a combination of colistin, amikacin and amphotericin B administered by vaporisation | |
FR2622113A1 (en) | Medicament comprising a combination of polymyxin B, amikacin and amphotericin B administered by vaporisation | |
FR2624739A1 (en) | Medicament comprising a combination of colistin, neomycin and amphotericin B administered by vaporisation | |
FR2624738A1 (en) | Medicament comprising a combination of colistin, sissomicin and amphotericin B administered by vaporisation | |
FR2622107A1 (en) | Medicament comprising a combination of polymyxin B, sissomicin and amphotericin B administered by vaporisation | |
FR2624740A1 (en) | Medicament comprising a combination of colistin, dibekacin and amphotericin B administered by vaporisation | |
FR2624016A1 (en) | Medicament comprising a combination of colistin, netilmicin and amphotericin B administered by vaporisation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BG BR DK FI HU JP NO RO SU US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE BJ CF CG CH CM DE FR GA GB IT LU ML MR NL SE SN TD TG |